A Case of Varicelliform Zoster in a Patient Treated with Etanercept for Ankylosing Spondylitis.
10.4078/jrd.2015.22.3.186
- Author:
Sun Hee NA
1
;
Eun Young NAM
;
Pyoeng Gyun CHOE
;
Wan Beom PARK
;
Nam Joong KIM
;
Myoung Don OH
;
Eun Young LEE
;
Nak Hyun KIM
Author Information
1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. NH.Kim.MD@gmail.com
- Publication Type:Case Report
- Keywords:
Herpes zoster;
TNFR-Fc fusion protein;
Ankylosing spondylitis
- MeSH:
Exanthema;
Herpes Zoster*;
Herpesvirus 3, Human;
Humans;
Incidence;
Spondylitis, Ankylosing*;
Tumor Necrosis Factor-alpha;
Etanercept
- From:Journal of Rheumatic Diseases
2015;22(3):186-189
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tumor necrosis factor-alpha (TNF-alpha) inhibitors are increasingly used in treatment of inflammatory disorders because of their immunomodulatory efficacy. Increased risk of infection is an adverse effect of anti-TNF-alpha therapy. The incidence rate and severity of herpes zoster is significantly higher in patients on anti-TNF-alpha therapy than in the general population. The clinical presentation of varicella zoster virus infection is also often atypical in these patients. We experienced a patient who presented with a disseminated varicelliform rash while on etanercept therapy for ankylosing spondylitis.